Drug ID:Drug156
Drug Name:PL8177
CID:88944400
DrugBank ID:NULL
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT05466890
Molecular Formula:C48H65N15O9
Molecular Weight:996.1 g/mol
Isomeric SMILES:CCCC[C@@H](C(=O)N[C@H]1CCC(=O)NC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N)NC(=O)C
Synonyms:CHEMBL3977876; SCHEMBL12657948; 16134B0YTH; BDBM250635; PL8177; PL-8177; US9447148, 9.3; AC-NLE-CYCLO-(GLU-HIS-D-PHE-ARG-DAP)-TRP-NH2; 1309111-58-7; L-TRYPTOPHANAMIDE, N-ACETYL-L-NORLEUCYL-L-.ALPHA.-GLUTAMYL-L-HISTIDYL-D-PHENYLALANYL-L-ARGINYL-3-AMINO-L-ALANYL-, (2->6)-LACTAM
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
No data available

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT05466890 Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC) PHASE2 ACTIVE_NOT_RECRUITING Palatin Technologies, Inc Ulcerative Colitis|Ulcerative Colitis Acute|Ulcer… DRUG: PL8177 Placebo|DRUG: PL8177 Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

A novel oral formulation of the melanocortin-1 receptor agonist PL8177 resolves…

PMID: 36891301
Year: 2023
Relationship Type: Treatment Score: 6.5

INTRODUCTION: PL8177 is a potent and selective agonist of the melanocortin 1 receptor (MC1R). PL8177 has shown efficacy in reversing intestinal infla…